Virginia Tech®home

Meet the Virginia Tech Cancer Research Alliance

Insert your title here

     

Meet the Virginia Tech Cancer Research Alliance

     

  • Redirect Item
    Irving "Coy" Allen, Ph.D., MBA , redirect

    Dr. Allen is an immunologist who explores the intersection between the immune system and cancer, specifically studying how unique families of pattern recognition receptors (PRRs) contribute to disease pathogenesis and inflammatory microenvironments.

  • Redirect Item
    Ilektra Athanasiadi, D.V.M. , redirect

    Dr. Athanasiadi studies radiation-induced brain injury to identify new drugs that can protect healthy brain tissue during irradiation, as well as palliative radiation therapy.

  • Redirect Item
    William T. Baumann, Ph.D. , redirect

    Dr. Baumann is a computational biologist who applies mathematical models to understand who breast cancer cells become resistant to treatment.

  • Redirect Item
    Warren K. Bickel, Ph.D. , redirect

    Dr. Bickel studies how a cancer diagnosis and future valuation influence health behaviors.

  • Redirect Item
    Brittany Ciepluch, D.V.M. , redirect

    Dr. Ciepluch is a surgical oncologist who studies treatments for aggressive forms of blood vessel cancer in dogs.

  • Redirect Item
    Daniela Cimini, Ph.D. , redirect

    Dr. Cimini studies the mechanics and dynamics of cell division and proliferation.

  • Redirect Item
    Rafael Davalos, Ph.D. , redirect

    Dr. Davalos applies engineering and biology from nano to macro scales, using electrical feedback to perform complex procedures - such as signal cell analysis, selective cell concentration, and cancer therapy - with precision and control.

  • Redirect Item
    Nick Dervisis, D.V.M., Ph.D. , redirect

    Dr. Dervisis studies neoplastic processes underlying cancers in cats and dogs, as well as the effects of genetic polymorphic variants on the metabolism and kinetics of anti-cancer agents.

  • Redirect Item
    Harry Dorn, Ph.D. , redirect

    Dr. Dorn is a chemist and nanoscientist who studies next generation instrumentation to visualize cancerous tumors.

  • Redirect Item
    Susan E. Duncan, Ph.D. , redirect

    Dr. Duncan studies the chemistry of the mouth and why many cancer patients report tasting a metallic flavor.

  • Redirect Item
    Carla Finkielstein, Ph.D. , redirect

    Dr. Finkielstein studies the molecular clocks that instruct cells when to grow, divide, and die, and how they're impaired in cancer cells, allowing for unbridled proliferation and the development of tumors. Finkielstein's research offers a critical foundation for the emerging field of chronotherapeutics - the study of time-of-day medicine - in cancer patients.

  • Redirect Item
    Michael J. Friedlander, Ph.D. , redirect

    Dr. Friedlander organized and oversees the Virginia Tech Cancer Research Alliance as the vice president for health sciences and technology at Virginia Tech. He is also executive director of the Fralin Biomedical Research Institute at VTC and a neuroscientist.

  • Redirect Item
    Robert Gourdie, Ph.D. , redirect

    Dr. Gourdie's laboratory tests new compounds targeting connexin channels for therapeutic use in wound healing, reducing scarring following breast reconstruction surgery, injury prevention, as well as applications to treat glioblastomas and aggressive, drug-resistant cancers.

  • Redirect Item
    Shawna Klahn, D.V.M. , redirect

    Dr. Klahn studies the safety and efficacy of new chemotherapeutic agents in pets, and also designs and implements new clinical trials to evaluate cancer therapies in canine and feline patients to advance veterinary and human cancer medicine.

  • Redirect Item
    Samy Lamouille, Ph.D. , redirect

    Dr. Lamouille's lab studies how cancer cells communicate and is developing novel therapeutic strategies to target these communication mechanisms to prevent metastases in human cancer progression.

  • Redirect Item
    Yong Woo Lee, Ph.D. , redirect

    Dr. Lee studies nanomaterials-mediated targeted drug delivery for cancer treatments, and the effective delivery of therapeutics across the blood-brain barrier.

  • Redirect Item
    Liwu Lee, Ph.D. , redirect

    Dr. Li studies the molecular and cellular mechanisms of inflammation, including the molecular pathways controlling immunity and inflammation, programming innate immune leukocytes, and the pathogenesis of acute and chronic inflammatory diseases.

  • Redirect Item
    Chang Lu, Ph.D. , redirect

    Dr. Lu is a chemical engineer who applies approaches in microfluidic biotechnology, precision medicine, epigenomics and gene regulation, and single cell analysis to understand cancer and immunology.

  • Redirect Item
    Jenny M. Munson, Ph.D. , redirect

    Dr. Munson studies how cancer increases fluid flow between cells, specifically across the invasive edge of the tumor, altering how tumors respond to drug therapies.

  • Redirect Item
    Keiko Murakami, D.V.M. , redirect

    Dr. Murakami studies multimodal cancer treatments, comparative oncology, canine tonsillar tumor and metastasis, stereotactic radiotherapy, and palliative cancer treatment.

  • Redirect Item
    Nicholas Rancilio, D.V.M. , redirect

    Dr. Rancilio researches stereotactic radiotherapy and hypofractionated radiation therapy, contouring guidelines, responses of healthy tissue to therapies, and palliative cancer care.

  • Redirect Item
    John H. Rossmeisl, Jr., D.V.M. , redirect

    Dr. Rossmeisl studies and develops novel therapeutics for primary brain tumors, including the exploration of medical devices that facilitate drug delivery to the central nervous system, and the identification of molecular and genetic signatures of malignant gliomas.

  • Redirect Item
    Eva Schmelz, Ph.D. , redirect

    Dr. Schemlz studies the role of dietary and endogenous sphinglolipids in cancer progression and metastasis on a molecular scale, as well as obesity and ovarian cancer.

  • Redirect Item
    Zhi Sheng, Ph.D. , redirect

    Dr. Sheng's laboratory explores the molecular pathways involved in cell survival and death to discover new cancer therapies, with a particular focus on glioblastoma multiforme.

  • Redirect Item
    Daniel Slade, Ph.D. , redirect

    Dr. Slade works at the interface of chemistry and biology to determine the role of the microbiome in cancer using chemical biology, x-ray crystallography, biochemistry, molecular genetics, enzymology, and cell biology.

  • Redirect Item
    Jamie Smyth, Ph.D. , redirect

    Dr. Smyth's laboratory studies the gap junction proteins involved in intercellular communication in the context of cardiovascular disease and cancer.

  • Redirect Item
    Jeff Stein, Ph.D. , redirect

    Dr. Stein studies human decision-making processes to prevent disease by improving medication adherence in breast cancer treatment, and increase public interest in cancer prevention tactics, such as cancer screenings and vaccinations.

  • Redirect Item
    Joanne L. Tuohy, D.V.M., Ph.D. , redirect

    Dr. Tuohy is a surgical oncologist who studies treatments for osteosarcomas, melanomas, carcinomas and other cancers.

  • Redirect Item
    John Tyson, Ph.D. , redirect

    Dr. Tyson is a computational biology who studies cell cycle regulation, estrogen responsiveness in breast cancer cells, innate immune responses, and stochastic modeling of protein regulatory networks.

  • Redirect Item
    Scott Verbridge, Ph.D. , redirect

    Dr. Verbridge researches and develops engineered platforms to better understand the tumor microenvironment, targets the altered physics of tumors with novel ablation modalities, and develops tissue engineering models to analyze host-pathogen interactions in the context of cancer.

  • Redirect Item
    Eli Vlaisavljevich, Ph.D. , redirect

    Dr. Vlaisavljevich studies therapeutic ultrasound, non-invasive tissue ablation, nanoparticle-mediated histotripsy, ultrasound-guided tissue regeneration, and ultrasonic neuromodulation.

  • Redirect Item
    Jia-Ray Yu, Ph.D. , redirect

    Jia-Ray Yu, Ph.D., studies the regulations of gene expression at the chromatin level. As chromatin is a highly compartmentalized structure, the temporo-spatial regulations of the chromatin-associated factors are crucial for their collective functions in shaping the epigenome. These natural principles are, however, often dysregulated in human diseases such as congenital developmental syndromes and a variety of cancers.